BR112012018343A2 - "composições imunogênicas" - Google Patents
"composições imunogênicas"Info
- Publication number
- BR112012018343A2 BR112012018343A2 BR112012018343A BR112012018343A BR112012018343A2 BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2 BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2
- Authority
- BR
- Brazil
- Prior art keywords
- pneumoniae
- immunogenic
- immunogenic compositions
- compositions
- isolated
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920002704 polyhistidine Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28923609P | 2009-12-22 | 2009-12-22 | |
| US32566010P | 2010-04-19 | 2010-04-19 | |
| PCT/CA2010/001977 WO2011075823A1 (en) | 2009-12-22 | 2010-12-20 | Immunogenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012018343A2 true BR112012018343A2 (pt) | 2017-06-27 |
Family
ID=44194860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018343A BR112012018343A2 (pt) | 2009-12-22 | 2010-12-20 | "composições imunogênicas" |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130183350A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2515938A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5894083B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120107121A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102802664B (cg-RX-API-DMAC7.html) |
| AR (1) | AR079712A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010335970B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012018343A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2783955A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL220576B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011075823A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201204628B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102939105B (zh) | 2009-12-22 | 2016-11-16 | 赛诺菲巴斯德有限公司 | 免疫原性组合物和相关的方法 |
| JP6046632B2 (ja) | 2010-12-03 | 2016-12-21 | サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ | 肺炎球菌に対する免疫用組成物 |
| EA201391456A1 (ru) | 2011-05-17 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | ВАКЦИНА ПРОТИВ Streptococcus pneumoniae |
| GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP6236086B2 (ja) * | 2012-10-17 | 2017-11-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物 |
| EP2931743A4 (en) * | 2012-12-14 | 2016-08-03 | Sanofi Pasteur Ltd | METHOD FOR ASSESSING IMMUNOGENICITY |
| AU2015228542A1 (en) * | 2014-03-10 | 2016-09-22 | Sanofi Pasteur Limited | Immunogenic compositions |
| KR101688960B1 (ko) * | 2014-06-11 | 2016-12-23 | 전남대학교산학협력단 | 스쿠티카충 백신 조성물 |
| SG11201706081SA (en) * | 2015-01-27 | 2017-08-30 | 3M Innovative Properties Co | Alum-containing coating formulations for microneedle vaccine patches |
| GB2556002B (en) * | 2015-07-07 | 2020-12-16 | Bluewillow Biologics Inc | Methods and compositions for nanoemulsion vaccine formulations |
| EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
| EP4395818A4 (en) * | 2021-09-02 | 2025-08-20 | Vaxcyte Inc | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC2178A1 (fr) * | 1988-12-16 | 1992-05-22 | Nederlanden Staat | Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| WO2000037105A2 (en) * | 1998-12-21 | 2000-06-29 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| GB0213622D0 (en) * | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| KR101916787B1 (ko) * | 2005-03-23 | 2019-01-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도 |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| JP2010501012A (ja) * | 2006-08-17 | 2010-01-14 | ザ ユーエービー リサーチ ファウンデーション | 免疫原性ＰｃｐＡポリペプチドおよびその使用 |
| WO2009012588A1 (en) | 2007-07-23 | 2009-01-29 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| AU2009208299B2 (en) * | 2008-02-01 | 2015-01-22 | Sanofi Pasteur Limited | Assay for diagnosing streptococcus pneumoniae |
| CA2748149C (en) * | 2008-12-24 | 2018-03-06 | Netherlands Vaccine Institute | Modified steptococcus pneumonia pneumolysin (ply) polypeptides |
-
2010
- 2010-12-20 CA CA2783955A patent/CA2783955A1/en not_active Abandoned
- 2010-12-20 CN CN201080064532.1A patent/CN102802664B/zh not_active Expired - Fee Related
- 2010-12-20 AU AU2010335970A patent/AU2010335970B2/en not_active Ceased
- 2010-12-20 JP JP2012545030A patent/JP5894083B2/ja not_active Expired - Fee Related
- 2010-12-20 US US13/515,093 patent/US20130183350A1/en not_active Abandoned
- 2010-12-20 EP EP10838456.1A patent/EP2515938A4/en not_active Withdrawn
- 2010-12-20 KR KR1020127019061A patent/KR20120107121A/ko not_active Abandoned
- 2010-12-20 WO PCT/CA2010/001977 patent/WO2011075823A1/en not_active Ceased
- 2010-12-20 BR BR112012018343A patent/BR112012018343A2/pt not_active IP Right Cessation
- 2010-12-22 AR ARP100104897A patent/AR079712A1/es unknown
-
2012
- 2012-06-21 IL IL220576A patent/IL220576B/en not_active IP Right Cessation
- 2012-06-21 ZA ZA2012/04628A patent/ZA201204628B/en unknown
-
2015
- 2015-11-15 IL IL242592A patent/IL242592A/en not_active IP Right Cessation
- 2015-12-25 JP JP2015254259A patent/JP2016104776A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130183350A1 (en) | 2013-07-18 |
| CN102802664A (zh) | 2012-11-28 |
| CN102802664B (zh) | 2017-04-05 |
| JP2016104776A (ja) | 2016-06-09 |
| IL220576B (en) | 2018-03-29 |
| AR079712A1 (es) | 2012-02-15 |
| EP2515938A1 (en) | 2012-10-31 |
| ZA201204628B (en) | 2013-02-27 |
| JP2013515015A (ja) | 2013-05-02 |
| AU2010335970A1 (en) | 2012-07-05 |
| CA2783955A1 (en) | 2011-06-30 |
| KR20120107121A (ko) | 2012-09-28 |
| AU2010335970B2 (en) | 2016-11-03 |
| IL242592A (en) | 2017-10-31 |
| JP5894083B2 (ja) | 2016-03-23 |
| WO2011075823A1 (en) | 2011-06-30 |
| EP2515938A4 (en) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018343A2 (pt) | "composições imunogênicas" | |
| GT201400097A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
| MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| BR112014006822A2 (pt) | proteínas de ligação ao antígeno cd27l | |
| BRPI0922220A8 (pt) | Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos | |
| BR112012012918A8 (pt) | Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes | |
| UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
| BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
| GT201200172A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes | |
| CO6551721A2 (es) | Moduladores de cinasa novedosos | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| ECSP12011787A (es) | Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| HN2012000798A (es) | Derivados de glicosidos y usos de los mismos. | |
| EA201300987A1 (ru) | Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2 | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
| CU20100059A7 (es) | Anticuerpos anti-esclerostina y proteínas funcionales | |
| BR112012021652A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| MX2021006784A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos. | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
| BR112012021656A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| BR112014025968A2 (pt) | composição e processo para o recurtimento e engraxe de couro, e couro preparado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |